Artwork
iconShare
 
Manage episode 515122410 series 2513286
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Featuring a slide presentation and related discussion from Dr Eunice S Wang, including the following topics:

  • All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) not eligible for intensive induction chemotherapy (0:00)
  • Quizartinib-based treatment approaches for FLT3-ITD-mutated and FLT3-ITD wild-type AML (5:21)
  • First- and second-generation IDH inhibitors for AML (17:40)
  • Updated results from the AUGMENT-101 Phase II study of the menin inhibitor revumenib for relapsed/refractory KMT2A-rearranged AML (22:59)
  • Phase Ib/II KOMET-001 study of ziftomenib for relapsed/refractory NMP1-mutant AML (26:42)
  • Novel combination approaches with menin inhibitors for AML (29:11)

CME information and select publications

  continue reading

765 episodes